News Center
- Approvals, Launches, & New Indications
- Pipeline Plus
- Research News
- Industry Trends
- Safety Issues
- Agency Actions
- Health Care Reform
- Guidelines
- Clinical Trials
- Drug Forecast
Current issue of P&T
P&T Past Issues
- 2022 (Vol. 47)
- 2021 (Vol. 46)
- 2020 (Vol. 45)
- 2019 (Vol. 44)
- 2018 (Vol. 43)
- 2017 (Vol. 42)
- 2016 (Vol. 41)
- 2015 (Vol. 40)
- 2014 (Vol. 39)
- 2013 (Vol. 38)
- 2012 (Vol. 37)
- 2011 (Vol. 36)
- 2010 (Vol. 35)
- 2009 (Vol. 34)
- 2008 (Vol. 33)
- 2007 (Vol. 32)
- 2006 (Vol. 31)
- 2005 (Vol. 30)
- 2004 (Vol. 29)
- 2003 (Vol. 28)
- 2002 (Vol. 27)
User login
Program reduced use of IV hydromorphone and morphine.
LATEST NEWS
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Table of Contents
Features
Program reduced use of IV hydromorphone and morphine.
Strict policies are needed to protect patients.
New treatmetnt has rapid onset of action.
Identifying the best evidence for DOAC use in certain populations.
Case Report
A Case Report of Thrombocytosis in a Patient Receiving Ciprofloxacin and Ceftriaxone
Case report points to risk of ciprofloxacin–ceftriaxone combination.
Perspective
Men might have benefited from getting a more complete ED story.
Departments
Health Care & Law
Prescription Washington
Congress divided on drug pricing legislation.
Medication Errors
Istradefylline (Nourianz) as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.
Drug Forcast
Meeting Highlights
Meeting Highlights
Industry announcements
- PROTEX® Launches PBX-CR(TM) for Temporary Medical Facility Use
- AIKido Pharma Inc. Adopts Plan to Preserve Valuable Tax Assets
- Cigna Makes It Easier For Hospitals To Focus On COVID-19 By Helping Accelerate Patient Transfers
- Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
- NCLEX® Exams to Resume in Limited Capacity March 25, 2020
- Familial Chylomicronemia Syndrome (FCS) Markets, Epidemiology and Forecast to 2030 - Featuring Emerging Drugs AKCEA-ANGPTL3-LRx, Lomitapide, AKCEA-APOCIII - LRx, and ARO-APOC3
- Cumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
- Fiat Chrysler Automobiles to Produce Face Masks for First Responders and Health Care Workers
- Global Hidradenitis Suppurativa (HS) Industry Assessment, 2020 Featuring InflaRx, Novartis Pharma, Incyte Corp, UCB Biopharma, and Janssen Pharma
- 2020 Contrast Media Market Assessment Report - Bayer and Daiichi Sankyo are the Leading Players
- Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015
- Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment
- Affinity Health Partners Brings Point Of Care COVID-19 Tests To Its Facilities
- Global Vasomotor Symptoms Market (2017 to 2030) - Featuring TherapeuticsMD, Astellas Pharma & Mitsubishi Tanabe Pharma Among Others
- Lamellar Ichthyosis (LI) Industry Outlook, 2030 Featuring Emerging Drugs TMB-001, Trifarotene (CD5789), and KB105